Skip to main content

Table 2 Frequent treatment-emergent adverse events

From: Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial

Adverse event, n (%)

Placebo (n = 68)

Vernakalant (n = 129)

Dysgeusia

1 (1.5)

19 (14.7)

Sneezing

0

11 (8.5)

Paraesthesia

1 (1.5)

8 (6.2)

Headache

2 (2.9)

7 (5.4)

Hypertension

3 (4.4)

6 (4.7)

Hypotension

3 (4.4)

5 (3.9)

Nausea

1 (1.5)

5 (3.9)

Increased blood pressure

0

4 (3.1)

Ventricular tachycardia

0

4 (3.1)

Bradycardia

0

4 (3.1)

Pain

3 (4.4)

0

  1. Treatment-emergent adverse events that occurred in more than 3 % of patients within 24 h of placebo or vernakalant administration